Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Task Force on Recommendations for Clinical Genetic Testing in Parkinson’s Disease

Christine Klein Rachel Saunders-Pullman
Christine Klein
Chair
Rachel Saunders-Pullman
Chair

MDS Staff Liaison: Sandra Videmsky

Task Force Purpose

While diagnosis of Parkinson's disease does not hinge on genetics, knowledge of gene carrier status may inform counseling patients on the expected rate of progression, risk of cognitive impairment, and selection of therapeutics, and this knowledge may be desired by the patient. There has been rapid development of experimental therapeutics targeting specific PD genetic mutations (LRRK2 and GBA), a number of which will soon enter clinical trial stage or already have. Up until now, the general state of practice was not to offer clinical genetic testing as it would not change patient management. However, patients’ right to self-determination as well as potentially actionable results, including through enrollment in clinical trials, raise the urgency to describe the landscape of testing practices and develop a consensus on recommendations.

As testing options expand, and gene-specific trials increase demand for testing, movement disorders clinicians may not be fully prepared to offer counseling and testing. All the recent developments in the field require critical review of the current status of genetic testing, as well as a careful review of associated ethical aspects.

The objectives of Task Force on Recommendations for Clinical Genetic Testing in Parkinson’s Disease are:

  • Convene a panel of international experts to review the current state of the field in PD genetic testing and counseling in various regions of the world
  • Review the ethical implications of genetic testing, counseling, and variable access to testing
  • Build consensus on the policies and recommendations for PD clinical genetic testing and counseling

 

Task Force Members

Roy Alcalay Deborah Mascalzoni
Soraya Bardien Niccolo Mencacci
Vincenzo Bonifati Marcelo Merello
Su Ju Chung Ivana Novakovic
Tatiana Foroud Gian Pal
Emilia Gatto Avner Thaler
Anne Hall Deborah Raymond
Nobutaka Hattori Mehri Salari
Inke König Ali Shalash
Tim Lynch Tanya Simuni
Karen Marder Oksana Suchowersky
  Carolyn Sue

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice